US FDA investigates third death after treatment with Sarepta's gene therapy Elevidys

  • The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' muscular disorder gene therapy Elevidys.